Articles related to Nephrology
Cannabis Users Have Higher Levels of Toxic Heavy Metals in Their Bodies: Study
New research reveals elevated levels of toxic heavy metals in marijuana users, highlighting the need for physicians to consider this when treating patients with conditions that may be impacted by heavy metal exposure.
Family Medicine/General Practice September 6th 2023
Clinical Risk Scores May Help Facilitate Empiric Antibiotic Treatment for cUTI
Clinical risk scores, as highlighted in a recent study, may provide a valuable tool for physicians in optimizing antibiotic treatment strategies for adult outpatients with cUTIs.
Internal Medicine August 9th 2023
Uncover the potential link between the widely used antibiotic cefepime and neurotoxicity in patients, particularly those with renal impairment, and understand how timely monitoring and management of cefepime levels could prove to be a vital aspect of patient care.
Hospitalist July 27th 2023
Metastatic Renal Cell Carcinoma: An ODYSSEY in the Real World of Patient Care
Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.
Nephrology July 25th 2023
Erectile Dysfunction Drugs Shown to Prevent Major Adverse Cardiovascular Events
Phosphodiesterase-5 inhibitors (PDE5i) have been found to reduce the risk of major adverse cardiovascular events in men with both coronary artery disease (CAD) and erectile dysfunction (ED), with tadalafil showing greater cardiac benefits compared to sildenafil, according to a study presented at the American Urological Association’s annual meeting. The retrospective study analyzed over 41,000 men with CAD and ED and found that those who took tadalafil or sildenafil had significantly lower 5-year risks of heart failure, myocardial infarction, and overall mortality compared to those who received no PDE5i treatment. Tadalafil recipients had even lower risks than sildenafil recipients across all categories. The study suggests that understanding the specific differences among PDE5i medications is crucial for addressing cardiac outcomes in patients with ED and CAD, with tadalafil potentially offering superior benefits due to differences in pharmacokinetics and longer duration of efficacy. However, further research is needed before definitive conclusions can be made regarding preferential prescription of tadalafil over other PDE5i medications.
Cardiology May 11th 2023
UPMC Researchers Hone Alerts for Drug-Associated AKI
At the 2023 HIMSS meeting, Dr. Sandra Kane-Gill discussed a new alert system being developed at UPMC to improve care for patients at risk for drug-associated acute kidney injury (AKI). According to Dr. Kane-Gill, drugs are involved in approximately 30% of AKI cases in hospitalized patients, but imprecise alert systems mean that at-risk patients could be overlooked. To address this challenge, Dr. Kane-Gill led a consensus-building project to identify 20 drugs that are probably or definitely nephrotoxic with routine use. UPMC has developed a prototype alert tool for AKI that uses this list of nephrotoxic drugs to accurately detect AKI in patients. Preliminary results indicate that for every five alerts generated, there was one case of drug-associated AKI, a higher accuracy rate than for other alert systems. Dr. Kane-Gill plans to further refine the alert tool before deploying it in practice at UPMC and is also interested in using machine learning to prevent episodes of kidney injury.
Clinical Pharmacology April 27th 2023